Published date: 31 January 2018

Last edited date: 31 January 2018

Closed future opportunity - This means that a potential contract has passed its approach to market date. A buyer can choose to consider any supplier interest or convert this notice into an opportunity ready for live procurement.


Approach to market date: 1 March 2018

Contract summary

Industry

  • Blood coagulants - 33141530

Location of contract

Any region

Value of contract

£92,500,000

Procurement reference

CM/PHS/15/5499

Published date

31 January 2018

Approach to market date

1 March 2018

Contract start date

1 July 2018

Contract end date

30 June 2019

Procedure type

Open procedure (above threshold)

Any interested supplier may submit a tender in response to an opportunity notice.

This procedure can be used for procurements above the relevant contract value threshold.

Contract is suitable for SMEs?

Yes

Contract is suitable for VCSEs?

No

Description

The products to be included in the procurement exercise are:
Recombinant factor VIIa,
PDFVIII containing vWF concentrate,
PDFIX concentrate,
PD pure vWF concentrate,
PD Factor VIII Inhibitor Bypassing Fraction (FEIBA),
PD Factor XIII concentrate,
PD Protein C Concentrate,
PD Fibrinogen concentrate,
Fresh Frozen Plasma,
PD FX concentrate,
Recombinant Porcine Factor VIII concentrate,
Prothrombin Complex Concentrate,
Emicizumab (humanised bispecific antibody).

More information

Spend profile

This table displays the spend profile of the notice
Financial year Budget
2018/2019 £69,375,000
2019/2020 £23,125,000

About the buyer

Address

Commercial Medicines Unit - NHS England
2nd Floor, Rutland House
Runcorn
WA7 2ES
England

Email

alison.greenwood3@nhs.net